GLP-1 Research Peptides and Body Weight: What the Published Evidence Shows

This article summarises what peer-reviewed trial literature reports about incretin receptor agonists and body weight. It is a research summary written for laboratory and educational context, not a weight-loss guide. It contains no dosing, administration or treatment advice, and the compounds discussed are supplied strictly for in-vitro laboratory research, not for human or animal use. Researchers should consult the primary publications referenced in our Published Research section for full methodology.

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from intestinal L-cells that, in the published physiology literature, influences insulin secretion, gastric emptying and central appetite signalling. Because appetite and satiety are part of energy balance, GLP-1 receptor signalling became a major focus of metabolic research, and synthetic receptor agonists are used as tools to study these pathways.

Semaglutide is the most extensively studied long-acting single GLP-1 receptor agonist. Large published randomised trials (the STEP programme) reported substantial mean reductions in body weight versus placebo in study populations over the trial periods. These results are frequently cited as the benchmark against which later multi-receptor agonists are compared. Our semaglutide-research-guide and the incretin-receptor-agonists-comparative paper summarise this literature with citations.

Tirzepatide is a dual GLP-1/GIP receptor agonist. In a head-to-head published trial against semaglutide (SURPASS-2) it was reported to produce greater reductions in glycated haemoglobin and body weight across its dose groups, and in obesity trials (SURMOUNT-1) the highest doses were associated with larger mean weight reductions than typically reported for single agonists. Head-to-head designs like SURPASS-2 are the most reliable basis for comparing the two classes.

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. Its published phase 2 trial reported the largest mean body-weight reductions of the three classes at the highest dose studied, an effect the literature attributes in part to glucagon-receptor engagement and energy expenditure. Because trials differ in duration, population and design, cross-trial percentage comparisons should be treated cautiously — only head-to-head studies allow direct between-class conclusions.

It is tempting to rank these compounds by headline percentage figures, but the published numbers come from different trials with different participants, durations and endpoints. The research literature is explicit that such cross-trial comparisons are confounded, and that the relative contribution of the GIP and glucagon components within multi-agonists remains an area of active investigation. For laboratory research the value lies in the distinct receptor pharmacology of each class, not in a simple league table.

Our Published Research section includes fully cited summaries of the underlying trials, including the comparative incretin-receptor-agonists-comparative review and individual compound papers. Each links to the original peer-reviewed publication so researchers can examine the primary data directly.